Top Page
Ascletis Pharma, Inc.
(1672)
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Ascletis Pharma, Inc. Business Overview & Revenue Model
Ascletis Pharma, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.36M | 1.28M | 56.60M | 54.09M | 76.88M | 35.00M |
| Gross Profit | 856.00K | 735.00K | 25.99M | -24.69M | 39.17M | -23.50M |
| EBITDA | -408.21M | -390.45M | -126.09M | -284.50M | -169.35M | -181.94M |
| Net Income | -258.57M | -300.94M | -144.72M | -314.84M | -199.02M | -209.24M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.12B | 2.49B | 2.66B | 2.83B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.95B | 2.30B | 2.48B | 2.50B | 2.71B |
| Total Debt | 4.27M | 7.63M | 8.42M | 4.24M | 2.75M | 1.59M |
| Total Liabilities | 129.00M | 158.41M | 148.94M | 117.16M | 100.89M | 85.42M |
| Stockholders Equity | 1.87B | 1.97B | 2.34B | 2.54B | 2.73B | 2.98B |
Cash Flow | ||||||
| Free Cash Flow | -313.25M | -343.73M | -163.32M | -156.85M | -154.13M | -123.87M |
| Operating Cash Flow | -311.15M | -341.58M | -144.16M | -142.45M | -146.93M | -84.91M |
| Investing Cash Flow | 1.62B | 978.91M | 149.84M | -1.30B | -274.49M | 132.30M |
| Financing Cash Flow | -72.54M | -103.51M | -81.50M | -1.42M | -31.10M | -21.67M |
Ascletis Pharma, Inc. Technical Analysis
Ascletis Pharma, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$34.70B | 40.39 | 27.37% | ― | 2.57% | 18.79% | |
54 Neutral | HK$12.29B | -43.93 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$9.58B | -16.48 | -42.46% | ― | 1219.19% | 25.15% | |
41 Neutral | HK$1.75B | -2.53 | -129.05% | ― | ― | -18.99% | |
40 Underperform | HK$10.19B | -47.78 | -21.42% | ― | 240.05% | -140.09% |
Ascletis Pharma, Inc. Corporate Events
Ascletis Pharma Inc. has announced an increase in its share repurchase program from HK$300 million to HK$500 million, citing the undervaluation of its stock and significant recent achievements in drug development. The company aims to enhance shareholder value and demonstrate confidence in its long-term growth prospects, with the repurchase funded by internal resources and conducted in compliance with relevant regulations.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced positive topline results from its U.S. Phase I study of ASC50, an oral small molecule IL-17 inhibitor. The study demonstrated that ASC50 is safe, well-tolerated, and exhibits a dose-proportional pharmacokinetic profile, supporting once-daily or potentially once-weekly dosing. The drug showed strong target engagement and is progressing to the next phase of clinical development for treating mild to moderate plaque psoriasis. These findings highlight ASC50’s potential as a best-in-class treatment option, leveraging Ascletis’s AI-assisted drug discovery technology.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that the China National Medical Products Administration has accepted its New Drug Application for denifanstat (ASC40), a first-in-class fatty acid synthase inhibitor for treating moderate-to-severe acne vulgaris. This acceptance marks a significant milestone for Ascletis as it moves closer to commercializing denifanstat, which has shown promising results in Phase III trials, demonstrating significant efficacy and a favorable safety profile.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced positive results from its 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist for obesity treatment. The study demonstrated significant weight loss and improved gastrointestinal tolerability compared to placebo, with no severe adverse events reported. These findings suggest a potential best-in-class profile for ASC30, positioning Ascletis favorably in the obesity treatment market as they plan to advance to Phase III trials.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the selection of its first oral GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, for clinical development. This drug candidate, developed using Ascletis’ proprietary technologies, has shown significantly higher bioavailability and potency compared to existing formulations in non-human primate studies. The company plans to submit an Investigational New Drug Application to the U.S. FDA in 2026, marking a significant step in addressing unmet needs in obesity treatment and strengthening Ascletis’ position in the pharmaceutical industry.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the co-formulation of ASC36, an amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist, both designed for once-monthly subcutaneous administration. The co-formulation demonstrated significant body weight reduction in preclinical studies and showed excellent stability, supporting its potential as a treatment for obesity. Ascletis plans to submit an Investigational New Drug Application to the FDA by the second quarter of 2026, marking a significant step in its clinical development pipeline.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced promising results from its Phase Ib studies of ASC30, both as an oral tablet and a subcutaneous injection, along with a preclinical study of a combination therapy involving ASC31 and ASC47. The oral tablet showed up to a 6.5% placebo-adjusted mean body weight reduction, with mild-to-moderate gastrointestinal adverse events, while the injection demonstrated an extended half-life supporting monthly and quarterly dosing schedules. These findings highlight the efficacy and safety of Ascletis’ obesity treatments and reinforce the company’s competitive positioning in the obesity drug market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$12.84 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, for clinical development targeting obesity. The preclinical studies indicate that ASC36 offers a significantly longer half-life and greater weight reduction compared to existing treatments, positioning it as a potentially best-in-class therapy. The company plans to submit an Investigational New Drug Application to the FDA by the second quarter of 2026, which could enhance its market positioning in the obesity treatment sector.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$12.84 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced it will present study results of its obesity treatment assets, including ASC30, ASC31, and ASC47, at ObesityWeek 2025 in Atlanta. These presentations highlight the company’s commitment to developing differentiated obesity treatments, with ASC30 being a new chemical entity with patent protection until 2044, and ASC31 and ASC47 showing promising results in preclinical studies.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has completed enrollment for a U.S. Phase IIa study of its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30, aimed at treating obesity. This milestone marks significant progress in the development of ASC30, which has demonstrated a 46-day half-life, supporting its potential as a once-monthly treatment option. Topline data from this study are expected in the first quarter of 2026, potentially impacting the company’s market positioning in obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has completed a pre-New Drug Application consultation with the China National Medical Products Administration for its drug denifanstat (ASC40), aimed at treating moderate-to-severe acne vulgaris. The drug has shown significant efficacy and a favorable safety profile in Phase III trials, with no severe adverse events reported. Ascletis plans to submit an NDA soon, which could enhance its market position in dermatological treatments in Greater China.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the selection of ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, for clinical development. ASC35 has shown promising results in preclinical studies, demonstrating a longer half-life and greater efficacy in weight reduction compared to tirzepatide, positioning it as a potentially best-in-class treatment for obesity. The company plans to submit an Investigational New Drug Application for ASC35 to the FDA by the second quarter of 2026, which could significantly impact its market positioning and offer scalability advantages in manufacturing.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced its intention to repurchase up to 96,284,628 shares, equivalent to 10% of its issued shares, under a repurchase mandate approved by shareholders. The company plans to use up to HK$300 million of its internal financial resources for this initiative, aiming to enhance shareholder value and reflect confidence in its long-term business prospects. The repurchase will be conducted in compliance with relevant regulations and will not adversely impact the company’s financial position.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the grant of 650,000 share options to 10 employee participants under its 2025 Share Option Scheme. This move is part of the company’s strategy to incentivize its workforce, with options exercisable over a period of five years starting from 2026. The grant aims to align employee interests with company performance, although no specific performance targets are required for the options to vest. The announcement reflects Ascletis Pharma’s commitment to employee engagement and retention, potentially strengthening its position in the competitive pharmaceutical industry.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.